Table 1:
Baseline characteristics
| Gemcitabine alone (n=36) | Gemcitabine plus berzosertib (n=34) | |
|---|---|---|
| Race | ||
| White | 34 (94%) | 30 (88%) |
| Asian | 0 | 2 (6%) |
| Unknown | 2 (6%) | 2 (6%) |
| Ethnicity | ||
| Not Hispanic or Latino | 34 (94%) | 30 (88%) |
| Hispanic or Latino | 1 (3%) | 2 (6%) |
| Unknown | 1 (3%) | 2 (6%) |
| ECOG performance status | ||
| 0 | 22 (61%) | 20 (59%) |
| 1 | 14 (39%) | 14 (41%) |
| Stage at diagnosis | ||
| II | 0 (0%) | 2 (6%) |
| III | 16 (44%) | 18 (53%) |
| IV | 14 (39%) | 9 (26%) |
| Unknown | 6 (17%) | 5 (15%) |
| Platinum-free interval* | ||
| ≤3 months | 13 (36%) | 13 (38%) |
| >3 to <6 months | 23 (64%) | 21 (62%) |
| Previous therapy lines | ||
| 1 | 10 (28%) | 3 (9%) |
| 2 | 18 (50%) | 20 (59%) |
| 3 | 5 (14%) | 6 (18%) |
| 4 | 2 (6%) | 4 (12%) |
| 5 | 0 | 1 (3%) |
| 8 | 1 (3%) | 0 |
| Previous therapy lines in platinum-resistant setting | ||
| 1 | 11 (31%) | 14 (41%) |
| 0 | 25 (69%) | 20 (59%) |
| Previous PARP inhibitor | ||
| Yes | 7 (19%) | 11 (32%) |
| No | 29 (81%) | 23 (68%) |
| Previous antiangiogenic therapy | ||
| Yes | 9 (25%) | 10 (29%) |
| No | 27 (75%) | 24 (71%) |
| BRCA mutated | ||
| Yes | 5 (14%) | 6 (18%) |
| No | 25 (69%) | 21 (62%) |
| Unknown | 6 (17%) | 7 (21%) |
*
Stratification factor. ECOG=Eastern Cooperative Oncology Group.